
MHE October 2023



Laws since 1996 have sought to assure that coverage of behavioral health treatments does not take a back seat to physical medicine. Amid a national crisis in mental illness and addiction, that new world of equality has not arrived. But is it on the way?

Two drugs that target the c-MET protein are in phase 3 trials.

Payers and hospitals are at odds over proposals that would level out payments to hospital outpatient departments and physician offices.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Study finds gaps in recommended cardiac amyloidosis testing
2
Study finds associations between particular speech patterns and particular schizophrenia symptoms
3
A conversation about pesticides and the rise of early-onset lung cancer in non-smokers, with Jorge Nieva, M.D.
4
Survodutide reduces liver fat in 84% of patients in phase 3 trial
5
